Modulation of Pantothenate Kinase 3 Activity by Small Molecules that Interact with the Substrate/Allosteric Regulatory Domain  by Leonardi, Roberta et al.
Chemistry & Biology
ArticleModulation of Pantothenate Kinase 3 Activity
by Small Molecules that Interact with the
Substrate/Allosteric Regulatory Domain
Roberta Leonardi,1 Yong-Mei Zhang,1,4 Mi-Kyung Yun,2 Ruobing Zhou,1 Fu-Yue Zeng,3,5 Wenwei Lin,3 Jimmy Cui,3
Taosheng Chen,3 Charles O. Rock,1 Stephen W. White,2 and Suzanne Jackowski1,*
1Department of Infectious Diseases
2Department of Structural Biology
3Department of Chemical Biology and Therapeutics
St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
4Present address: Department of Biochemistry andMolecular Biology, Medical University of South Carolina, 173 Ashley Avenue, Charleston,
SC 29425, USA
5Present address: Burnham Institute of Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
*Correspondence: suzanne.jackowski@stjude.org
DOI 10.1016/j.chembiol.2010.06.006SUMMARY
Pantothenate kinase (PanK) catalyzes the rate-
controlling step in coenzyme A (CoA) biosynthesis.
PanK3 is stringently regulated by acetyl-CoA and
uses an ordered kinetic mechanism with ATP as
the leading substrate. Biochemical analysis of site-
directed mutants indicates that pantothenate binds
in a tunnel adjacent to the active site that is occu-
pied by the pantothenate moiety of the acetyl-CoA
regulator in the PanK3,acetyl-CoA binary complex.
A high-throughput screen for PanK3 inhibitors and
activators was applied to a bioactive compound
library. Thiazolidinediones, sulfonylureas and ste-
roids were inhibitors, and fatty acyl-amides and
tamoxifen were activators. The PanK3 activators
and inhibitors either stimulated or repressed CoA
biosynthesis in HepG2/C3A cells. The flexible allo-
steric acetyl-CoA regulatory domain of PanK3 also
binds the substrates, pantothenate and pantetheine,
and small molecule inhibitors and activators to
modulate PanK3 activity.
INTRODUCTION
Pantothenate kinases (PanK) are the regulatory enzymes that
control the rate of CoA biosynthesis and the concentration of
intracellular CoA (Leonardi et al., 2005b). In mammals, there
are four characterized isoforms of PanK, PanK1a, PanK1b,
PanK2, and PanK3, encoded by three genes. All four proteins
share homologous catalytic core domains of approximately
350 amino acids. The enzymes function as homodimers with
two equivalent active sites formed by a head-to-tail juxtaposition
of the monomers. PanK3 and PanK1b contain only the catalytic
core domain (Rock et al., 2002; Zhang et al., 2005), and PanK1a
and PanK1b arise from the PANK1 gene through the use of alter-892 Chemistry & Biology 17, 892–902, August 27, 2010 ª2010 Elsevinate initiation exons (Rock et al., 2002). PanK1a differs from
PanK1b and PanK3 in having a 230 residue amino terminal
extension whose function is not understood. The PANK2 gene
encodes a protein that is processed twice during its localization
to the mitochondria in humans (Ho¨rtnagel et al., 2003), but
mouse PanK2 lacks these signals and remains in the cytosol
(Leonardi et al., 2007b). A common feature of mammalian PanKs
is that they are regulated via feedback inhibition by acetyl-CoA
(Leonardi et al., 2005b), which is the primary mechanism that
controls kinase activity and the intracellular level of CoA (Rock
et al., 2002, 2003; Zhang et al., 2005). PanKs bind acetyl-CoA
with high affinity and the ligand remains bound to the enzymes
through purification (Hong et al., 2007). Acyl-carnitines activate
PanK2 by displacing acetyl-CoA from the enzyme (Leonardi
et al., 2007a).
The discoveries that mutations in the PANK2 gene are linked
to pantothenate kinase-associated neurodegeneration (PKAN)
(Zhou et al., 2001) and the connection between PANK1 and
insulin levels revealed in a recent genome-wide association
study (Sabatti et al., 2009) have focused interest on under-
standing PanK. The first structure was the Staphylococcus
aureus PanK (SaPanK) complex with AMPPNP,Mg2+ (Hong
et al., 2006). This structure, coupled with site-directed mutagen-
esis studies, revealed the residues important for nucleotide
binding and catalysis; however, SaPanK is not regulated by
acetyl-CoA (Leonardi et al., 2005a). The acetyl-CoA binding
site was revealed in structures of the PanK1b and PanK3 binary
complexes with acetyl-CoA. The regulator docks in a linear
pocket adjacent to the active site formed by residues derived
from both monomers (Hong et al., 2007). The adenine portion
of acetyl-CoA is not visible in these structures, but it was sug-
gested that the ADP of CoA extends into the ATP binding cleft
to block catalysis, thus explaining how acetyl-CoA inhibition is
competitive with respect to ATP (Hong et al., 2007).
The understanding of PanK functions is limited by the dearth of
information on the biochemistry of the PanKs. The structures
of the PanK3 binary complexes do not reveal the binding pocket
of the pantothenate substrate, but we did visualize the pantothe-
nate in the structurally related Pseudomonas aeruginosa PanKer Ltd All rights reserved
Figure 1. Biochemical Mechanism and
Structure of PanK3
(A and B) Graphical analysis of product inhibition
experiments using fixed concentrations of ADP
and variable concentrations of either ATP (A) or
pantothenate (B) showed that ADP was competi-
tivewithATPanduncompetitivewithpantothenate.
(C) These data are consistent with a compulsory
ordered kineticmechanismwith ATP as the leading
substrate and ADP as the last product to leave the
enzyme.
(D) Detailed interactions of the pantothenate
portion of CoA within the tunnel formed from the
stable b10 and b11 platform of the ATP-binding
domain (purple) on one subunit (yellow) and the
flexible loop between a70 and b130 that reaches
over from the opposite monomer (cyan). The resi-
dues investigated by site-directed mutagenesis
are shown. Acetyl-CoA is shownas aball-and-stick
representation (gray carbons) and the P loop is
colored magenta. Red spheres are water mole-
cules and hydrogen bonds are indicated by dotted
red lines. Note that in this ‘‘open’’ conformation, the
general base E138 is not positioned to perform
catalysis and the adenine ring of acetyl-CoA
acts as a wedge to prevent domain closure. See
Supplemental Experimental Procedures for struc-
ture determination and Table 1 for the structural
statistics.
(E) PanK3(S195V) was refractory to acetyl-CoA
inhibition compared with PanK3. PanK3 activity in
the absence of acetyl-CoA was set at 100%.
PanK3(S195V) has a KM defect for pantothenate
(see text). The data were duplicate measurements
with the standard error indicated by the bars.
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Substrate and Inhibitor Binding to PanK(PaPanK). However, an equivalent pocket is absent in the mam-
malian PanKs due to distinct differences in their dimer interface
compared with PaPanK. Therefore, we hypothesized that panto-
thenate occupies the same pocket as the pantothenate moiety
of acetyl-CoA (Hong et al., 2007). If correct, the extensive
acetyl-CoA binding surface and the flexibility of the enclosing
flap suggest that a biochemical screen would identify PanK
inhibitors and activators with the potential to regulate interme-
diary metabolism in human diseases. PanK inhibitors would be
used to explore the relationship between glucose homeostasis
and hepatic CoA levels that were revealed by the treatment of
animals with the pantothenate antimetabolite, hopantenate
(Zhang et al., 2007) and by the analysis of Pank1 knockout
mice (Leonardi et al., 2010). Activators, like furosemide, an acti-
vator of Plasmodium falciparum PanK (Lehane et al., 2007),
could potentially increase CoA levels and alleviate the deficiency
in CoA biosynthesis that arises from PanK2 inactivation in PKAN
disease. PanK3 was selected to initiate this study because it is
ubiquitously expressed and can be purified in the quantities
necessary for structural analysis, site-directed mutagenesis
and high-throughput screening (HTS).RESULTS
Ordered Mechanism for PanK3
The kinetic parameters for ATP and pantothenate, and the
kinetic mechanism for PanK3 were determined to provide theChemistry & Biology 17, 89basis for the interpretation of the effects of mutations on enzyme
activity and substrate binding. The KM values for ATP and panto-
thenate were 311 ± 53 mMand 14 ± 0.1 mM, respectively. Product
inhibition experiments showed that ADP was a competitive
inhibitor of PanK3 with respect to ATP (Figure 1A) and a mixed-
type inhibitor with respect to pantothenate (Figure 1B). These
product inhibition data show that PanK3 operates via an ordered
kinetic mechanismwith ATP as the leading substrate (Figure 1C).
An ordered kinetic mechanism is common for kinases and is
also found in Escherichia coli pantothenate kinase (Song and
Jackowski, 1994), which has a completely different three-dimen-
sional structure than PanK3 and belongs to a different kinase
family (Yun et al., 2000).Structure-Guided Site-Directed Mutagenesis
As part of this study, we determined a higher resolution structure
(Table 1) of the PanK3,acetyl-CoA complex than the one previ-
ously reported (Hong et al., 2007). The structures are very similar
except that improved resolution revealed the location of the
30,50-AMP portion of acetyl-CoA that was previously not visible
(Figure 1D). The phosphate on the 30-position of the ribose inter-
acts with Lys24 and Arg325, and the 20-hydroxyl group forms
a hydrogen bond with the backbone amide of Gly116. The
adenine ring is loosely held by interactions with Lys135 and
Gly116, and Ile2530 and Try2540 from the opposite monomer
(Figure 1D). We anticipated that the ATP-like moiety of acetyl-
CoA would occupy the ATP binding site of PanK3, but2–902, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 893
Table 1. Statistics of Data Collection and Refinement
Parameter PanK3,Acetyl-CoA
Data Collectiona
Space group P21
Unit cell dimensions (A˚)
a, b, c (A˚) 56.7, 180.4, 77.4
a, b, g () 90.0, 95.5, 90.0
Resolution range (A˚) 50.0–1.98 (2.05–1.98)
Beamline ID22, SER-CAT
Wavelength (A˚) 0.97921
Rsym
b 0.086 (0.473)
I/s 17.5 (1.8)
Completeness (%) 98.8 (90.2)
Redundancy 3.6 (2.7)
Unique reflections 106,621
Refinementa
Resolution range (A˚) 50.0–1.98 (2.03–1.98)
No. of reflection 100,924 (6914)
Completeness (%) 99.1 (92.1)
Rwork 0.185 (0.222)
Rfree
c 0.232 (0.268)
No. of atoms
Protein 10,807
Nonprotein 775
Mean B overall (A˚2) 33
Rmsd from ideal values
Bond lengths (A˚) 0.014
Bond angles () 1.462
Ramachandran plot
Most favored region (%) 92.6
Additional allowed region (%) 6.9
Generously allowed region (%) 0.4
Disallowed region (%) 0.1
a Values in parentheses refer to the highest resolution shell.
b Rsym =
Pj(I- < I >)j/P(I), where I is the observed intensity.
c Rfree is the R value obtained for a test set of reflections consisting of
randomly selected 5% subset of the data set excluded from refinement.
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Substrate and Inhibitor Binding to PanKcomparison with the SaPanK,ATP,Mg2+ binary complex
structure (Hong et al., 2006) shows that this is not the case.
The modes of binding are similar, but the adenine ring of
acetyl-CoA engages a different site at the interface of the two
subdomains. In the SaPanK,ATP,Mg2+ binary complex, these
two domains are in a closed conformation that is required for
catalysis (Hong et al., 2006), but the adenine portion of acetyl-
CoA sits in the ATP binding cleft, holding it in an open conforma-
tion that does not allow ATP to enter the active site and engage
the P loop.
The site-directed mutagenesis strategy was to identify a side
chain modification in the pantothenate-binding portion of the
acetyl-CoA tunnel that renders PanK3 refractory to acetyl-CoA
inhibition. The contacts between acetyl-CoA and PanK3 are
similar to those responsible for the b-strand interactions within
the b sheet of a protein (Figure 1D). The a70-b130 loop reaches894 Chemistry & Biology 17, 892–902, August 27, 2010 ª2010 Elseviover from the opposite subunit to form the ‘‘lid’’ of the tunnel,
and only interacts with acetyl-CoA via the backbone carbonyls
of Ala2690 and Val2680 and the amide nitrogens of 40-phospho-
pantetheine. These interactions cannot be altered by amino
acid replacements. However, Ser195 and Arg207 on strands
b10 and b11, respectively, have side-chain interactions with
acetyl-CoA (Figure 1D). The side chain of Ser195 extends into
the tunnel to form a hydrogen bond with the pantothenate
carbonyl oxygen, and we mutated this residue to a valine to
introduce a bulkier side chain that could compromise the dock-
ing of ligands within the tunnel by steric hindrance. The guanidi-
nium group of Arg207 has a strong interaction with the carbonyl
oxygen of the b-alanine segment of the 40-phosphopantetheine
(Figure 1D), and we hypothesized that an equivalent interaction
with the terminal carboxyl group of pantothenate would serve
to register the substrate within the tunnel. Arg207 was therefore
changed to an alanine to eliminate this potential interaction.
Finally, alanines 2670 and 2690 mediate tight van der Waals inter-
actions with the pantothenate moiety. Ala267 contacts the mer-
captoethanolamine group and Ala269 interacts with the methyl
groups (Figure 1D). Both were mutated to Phe to sterically inter-
fere with ligand binding.
The PanK3(R207A), PanK3(A267F), and PanK3(A269F)
mutants were all catalytically inactive (<1% wild-type activity
under all conditions tested) despite being correctly folded based
on their Stoke’s radius determined by gel filtration chromatog-
raphy (not shown). Furthermore, the proteins bound ATP nor-
mally based on the KD for the binding of the fluorescent ATP
analog TNP-ATP (see Supplemental Experimental Procedures
available online). PanK3 exhibited an apparent KD for TNP-ATP
of 3.6 ± 0.9 mM, and the values determined for PanK3(R207A)
(3.0 ± 0.3 mM), PanK3(A267F) (3.1 ± 0.8 mM), and PanK3
(A269F) (5.4 ± 0.8 mM) indicated that the inactive mutant
enzymes were not defective in ATP binding. These data sup-
ported the idea that the allosteric domain of the protein involved
in the binding of the 40-phosphopantetheine portion of acetyl-
CoAwas also critical for either pantothenate binding or catalysis.
PanK3(S195V) was the most informative mutant. PanK3
(S195V) was a catalytically active protein that retained 30% of
the wild-type specific activity under our standard assay condi-
tion but was refractory to inhibition by acetyl-CoA (Figure 1E),
illustrating that the introduction of the bulky valine group into
the tunnel prevented the binding of acetyl-CoA. The kinetic anal-
ysis of PanK3(S195V) showed an ATP KM = 191 ± 27 mM
compared with 311 ± 53 for PanK3, but PanK3(S195V) exhibited
a 10-fold increase in the KM for pantothenate (151 ± 16 mM)
compared with PanK3 (14 ± 0.1) (p < 0.01). The simultaneous
perturbation of both pantothenate and acetyl-CoA binding in
the PanK3(S195V) mutant provided strong support for the idea
that the two ligands share a common binding site on the protein.
Utilization of Pantetheine by PanK3
If pantothenate binds at approximately the same location as
the longer pantetheine portion of acetyl-CoA, then substrate
analogs that extend from the carboxyl end of pantothenate
would be anticipated to also be substrates. PanK3 phosphory-
lates hopantenate, a pantothenate analog that is 1 carbon longer
than pantothenate (Zhang et al., 2007), and it is also able to phos-
phorylate the N-pentyl- and N-heptyl-pantothenamide analogser Ltd All rights reserved
Table 2. Bioactive PanK3 Inhibitors with an IC50 < 10 mM
Inhibitor
IC50
(mM) Annotated Activity
Fusidic acid 0.1 Antibacterial
1,4-PBIT dihydrobromide 0.4 iNOS and eNOS inhibitor
WIN 62577 0.7 NK1 tachykinin receptor
antagonist
Pioglitazone hydrochloride 1.0 Antidiabetic
Reactive Blue 2 1.3 P2Y receptor antagonist
Ephedrine hydrochloride 1.6 Decongestant, bronchodilator
Psi-Rhodomyrtoxin 1.6 Natural product from
Rhodomyrtus macrocarpa
Rosiglitazone 1.7 Antidiabetic
Pregnenolone sulfate 2.5 Allosteric modulator
of GABA-A receptors
Tyrphostin AG 528 3.0 Protein tyrosin kinase inhibitor
Dehydroisoandrosterone
sulfate
3.5 Allosteric modulator
of GABA-A receptors
18a-glycyrrhetinic acid 3.6 Anti-inflammatory
Ro 41-0960 3.9 COMT inhibitor
Glipizide 5.2 Antidiabetic
Chloranil 5.9 Antipsoriatic
Glyburide 6.8 Antidiabetic
Hexachlorophene 8.8 Topical anti-infective
Tyrphostin AG 808 9 Protein tyrosine kinase inhibitor
GW5074 9.2 cRaf1 kinase inhibitor
Tolfenamic acid 9.2 Non steroidal anti-inflammatory
A bioactive compound library of 3200 unique compounds was initially
screened at 12 mM to identify modulators of PanK3 activity. The inhibitors
were then individually rescreened using a ten-point concentration series
in triplicate, and the IC50 values were calculated based on fitting the
30 data points to a single site binding model (see Figure S1). The IC50
values were rounded to the nearest 0.1 mM.
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carboxyl group (Virga et al., 2006). These data illustrate that
extensions of pantothenate from the carboxyl end of the mole-
cule are readily tolerated by PanK. Thus, pantetheine is a likely
substrate for PanK3, although the physiological significance of
this reaction is unclear. PanK3 readily phosphorylated pante-
theine with an apparent KM of 23 ± 2 mM. The KM of PanK3
(S195V) for pantetheine (59 ± 3 mM) was higher than for PanK
(p < 0.01). These findings corroborate the conclusion that the
pantothenate/pantetheine substrate binding site was compro-
mised in PanK3(S195V).
Bioactive Compound Library Screen
A biochemical high-throughput screen (HTS) was developed to
identify small molecule inhibitors and activators of PanK3 using
a two-step luminescence-based assay similar to the assay
employed to screen other kinases, likeMycobacterium tubercu-
losis pantothenate kinase (Habig et al., 2009). In the first step,
PanK3 was incubated with the substrates and the test com-
pound, and in the second step, a mixture of luciferase and lucif-
erin was added and the luminescence measured. The measured
signal was proportional to the amount of ATP remaining after the
PanK3 reaction, so that activators and inhibitors produced either
a low or high signal, respectively, compared with the DMSO
control. To enable the detection of both activators and inhibitors,
the substrate concentrations, amount of PanK3, and incubation
time were adjusted so that 35% of ATP was consumed in
control reactions. The reactions were started by the addition of
PanK3, which was stable at 4C for R24 hr. One caveat to this
screen is that it would not detect PanK competitive inhibitors
that are also substrates if their affinities for PanK were similar
to pantothenate (Spry et al., 2010).
The PanK3HTS assaywas used to screen a compound collec-
tion containing 5600 (3200 unique) molecules with known biolog-
ical activity. All compounds were initially screened at 12 mM, and
the Z0 parameter was used to assess assay performance (Zhang
et al., 1999). Z0 was consistent throughout the screen with an
average value >0.5, illustrating that the assay was stable and
reproducible from plate to plate (Figures S1A–S1C). We also
did not observe any plate well positional trends based on the
average activities of each well in all plates screened (data not
shown). A summary of the entire data set calculated to identify
both inhibitors and activators is shown in Figures S1D and
S1F. Cutoff values of >25% activation and >30% inhibition of
PanK3 identified 8 unique activators (13 total) and 44 unique
inhibitors (65 total). A ten-point dose-response curve in triplicate
was subsequently obtained to validate each of the primary hits
using the HTS platform (Figures S1E and S1G). This validation
step led to the exclusion of six inhibitors (13.6%) and one acti-
vator (12.5%) as false positives.
PanK3 Inhibitors from the HTS
The HTS identified and confirmed 20 inhibitors of PanK3 with an
IC50 <10 mM (Table 2). We focused our mechanistic analyses on
three classes of inhibitors, thiazolidinediones, sulfonylureas, and
steroids, which hadmultiple hits in the HTS. The two thiazolidine-
diones detected in the screen were rosiglitazone and pioglita-
zone (Table 2). This class of compounds are best known as
PPARg ligands that are widely used for the treatment of type 2Chemistry & Biology 17, 89diabetes (Gale, 2001; Lehmann et al., 1995; Mudaliar and Henry,
2001). The two sulfonylurea inhibitors identified in the assay,
glipizide and glyburide (Table 2), are second-generation sulfonyl-
ureas that stimulate insulin secretion from the pancreatic b cells
and are widely prescribed oral antidiabetic drugs (Bell, 2004;
Boyd et al., 1990). The most potent inhibitor was fusidic acid,
one of three steroid-like compounds that were identified in the
screen (Table 2). Fusidic acid is an antibiotic effective against
methicillin-resistant S. aureus and other Gram-positive bacteria,
but it is not extensively used due to hepatotoxic side effects
(Bode et al., 2002; Humble et al., 1980). The two other steroid-
like inhibitors, pregnenolone sulfate and dehydroisoandroster-
one sulfate, are synthesized in the brain and act as modulators
of neurotransmitter receptors (Gibbs et al., 2006; Vallee et al.,
2001). Additional representative members of each of the three
structural classes were analyzed further to validate the HTS,
derive initial structure-activity relationship (SAR) information,
and provide insights into their mechanism of action (Figure 2).
Fusidic acid had an IC50 of 0.1 mM in the HTS assay (Table 2).
Analogs of this structurally complex, steroid-like natural product
(Figure 2A) were not available, so we focused on investigating
the SAR in a series of steroids related to the two identified in2–902, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 895
Figure 2. Structures of the Biochemically
Characterized Inhibitors and Activators
Identified in the HTS
(A) Steroids and fusidic acid.
(B)ThiazolidedioneandnonthiazolidinedionePPARg
ligands.
(C) Sulfonylurea andnonsulfonylurea insulin secreta-
gogues.
(D) PanK3 activators.
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Substrate and Inhibitor Binding to PanKthe HTS (Table 2). Sulfated steroids and their nonsulfated coun-
terparts (Figure 2A) were tested as PanK3 inhibitors using the
radiochemical assay at a concentration of 100 mM (Figure 3A).
With the exception of estradiol sulfate, which had no effect on
PanK3, pregnenolone, dehydroisoandrosterone, and estrone
sulfates inhibited the enzyme more potently than their nonsul-
fated versions. Conversion of dehydroisoandrosterone sulfate
to estrone sulfate through aromatization of the A ring of the ster-
ane core reduced inhibitor activity. Pregnenolone and choles-
terol have different substituents replacing the ketone at C17,
and these compounds were weak PanK3 inhibitors, highlighting
the importance of this functional group at C17. Dehydroisoan-
drosterone decreased the enzyme activity even in the absence
of the sulfate group at C-3. This SAR information revealed that,
in addition to the sulfate group on the C-3, a keto or methyl
keto group on C-17 was also important for inhibiting PanK3.
Although these data validated the HTS approach and revealed
a clear SAR among the steroids tested, their weak potency
and chemical properties make them undesirable scaffolds to
develop as selective biological modifiers, and their mechanism
of action was not investigated further.
The thiazolidinediones and sulfonylureas are used in the treat-
ment of type 2 diabetes. The thiazolidinediones identified in the
HTS and two additional members of this compound class not
present in the library, ciglitazone and MCC-555 (Figure 2B),896 Chemistry & Biology 17, 892–902, August 27, 2010 ª2010 Elsevier Ltd All rights reservedhave similar potencies as PanK3 inhibi-
tors (Figure 3B). MCC-555 was the most
potent of the compounds with an IC50 of
5 mM (Figure 3B). The potent PPARg
ligands, GW9662 and GW1929, either
had no effect or very weak activity against
PanK3 (Figure 3B), illustrating that PPARg
activity can be separated from PanK
activity. GW501516, a PPARd selective
ligand (Sznaidman et al., 2003) that has
a related thiazole ring instead of a thiazoli-
dinedione ring (Figure 2B), showed weak
activity against PanK3 (IC50 100 mM).
The sulfonylureas, glyburide and glipizide
(Figure 2C), were confirmed as PanK3
inhibitors (IC50 = 8.5 mM) by the radioac-
tive assay (Figure 3C). Tolbutamide,
a first-generation sulfonylurea, was
ineffective against the enzyme. The non-
sulfonylurea insulin secretagogues,
nateglinide and repaglinade (Figure 2C),
were also inactive (IC50 > 100 mM) (Fig-
ure 3C). These data showed that, amonginsulin secretagogues, only the sulonylurea series were PanK
inhibitors.
Thiazolidinediones and Sulfonylureas Target
the Acetyl-CoA Binding Site
Our structure of the PanK3,acetyl-CoA binary complex showed
that the adenine moiety of acetyl-CoA docks into the cleft that
binds ATP, prevents ATP binding and maintains the enzyme
in an ‘‘open’’ conformation (Figure 1D). To test whether any of
the thiazolidindiones and sulfonylureas bind to the regulatory
acetyl-CoA binding site, a representative member of each group
(MCC-555 and glyburide) was tested for their ability to inhibit
PanK3(S195V) and S. aureus PanK (SaPanK). PanK3(S195V) is
refractory to feed-back inhibition by acetyl-CoA (Figure 1E),
and SaPanK is a bacterial PanK with the same structural fold
as PanK3, but is not allosterically regulated by acetyl-CoA
(Leonardi et al., 2005a). A comparison between the structures
of the PanK3,acetyl-CoA (Figure 2A) and SaPanK,AMP-
PNP,Mg2+ complexes (Hong et al., 2006) suggested that
acetyl-CoA binding to SaPanK may be prevented in part by the
side chains of Tyr240 and Arg244 that substitute for Ala337
and Trp341, respectively, in PanK3 (Hong et al., 2007). We also
note that the loop in SaPanK corresponding to the a70-b130
loop in PanK3 that forms the ‘‘lid’’ of the active site tunnel is
disordered in SaPanK,AMP-PNP,Mg2+, consistent with this
Figure 3. PanK3 Inhibition by Selected Compounds
Identified by HTS
The PanK3 radioactive assay described in Experimental
Procedures was used to test selected HTS hits and related
molecules.
(A) Steroids and their sulfate derivatives were tested at 100 mM
concentration against PanK3.
(B) The thiazolidinedione PPARg ligands evaluated were
rosiglitazone (d), pioglitazone (B), ciglitazone (-), and MCC-
555 (,). Three structurally unrelated PPARg ligands
GW501516 (D), GW1929 (A), and GW9662 (:) were also
assayed.
(C) Sulfonylurea insulin secretagogues identified in the HTS,
glyburide (d) and glipizide (B) were validated PanK3 inhibitors.
Three other insulin secretagogues analyzed were tolbutamide
(,), repaglinide (-), and nateglinide (A). PanK3 activity in the
presence of DMSO only was set at 100%.
(D) PanK3(S195V) was refractory to inhibition byMCC-555 (,)
and glyburide (-).
(E) SaPanK was not inhibited by either MCC-555 (,) or glybur-
ide (-). PanK3activity in thepresence ofDMSOonlywas set at
100%. The specific activities used as 100% in these assays
were: PanK3, 149 ± 2 nmol/min/mg; PanK3(S195V), 48 ±
3 nmol/min/mg; SaPanK, 4.2 ± 1.0 mmol/min/mg. The data
were duplicate measurements with the standard error indi-
cated by the bars. IC50 values ± standard error were derived
from fitting the 14-point data set to a single-site binding model
usingGraphPad software. See Figure S2 for the kinetic analysis
ofMCC-555andglyburide inhibition of PanK3andFigure S3 for
the isoform selectivity of MCC-555, glyburide, and tamoxifen.
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the pantothenate binding site. PanK3(S195V) and SaPank were
both refractory to MCC-555 and glyburide inhibition (Figures
3D and 3E), suggesting that the binding site for these two inhib-
itors overlaps with the pantothenate/acetyl-CoA site within the
substrate binding tunnel. The kinetic mechanism underlying
PanK3 inhibition by MCC-555 and glyburide was also investi-
gated, and they both were uncompetitive with respect to ATP
and pantothenate (Figure S2). Based on the compulsory ordered
kinetic mechanism of PanK3 (Figure 1C), this kinetic analysis
indicates that both compounds bind to the PanK3,ADP complex
(Figure S2E). Thus, the thiazolidinedione and sulfonylureas
appear to interact in the vicinity of the acetyl-CoA regulatoryChemistry & Biology 17, 892–902, Augussite to inhibit PanK3 activity but may not extend
into the ATP binding cleft to prevent binding of the
nucleotide.
Identification of PanK3 Activators
PanK3 activators validated by HTS and with an
EC50 <10 mM are listed in Table 3. These
compounds were further tested using the radioac-
tive PanK assay, and 1,4-napthoquinone and
phenylmercuric acid were not confirmed as
PanK3 modulators. The HTS assay relied on the
signal produced by the luciferase reaction and
a compound that dose-dependently inhibited this
step would therefore appear as an activator in this
assay, but not in the radiochemical assay. Thus,
the HTS assay only identified two bona fide activa-tors, and produced a higher rate of false positive hits compared
with the inhibitor hits.
Oleoyl-ethanolamide was one of the confirmed activators
(Figure 2D; Table 3). This PPARa ligand (Hansen and Diep, 2009;
Schwartz et al., 2008) belongs to a class of phosphatidylethanol-
amine-derived metabolites referred to as endocannabinoids, and
it activated PanK3 with the same potency as palmitoylcarnitine,
a known activator of both PanK2 (Leonardi et al., 2007a) and
PanK3 (Table 3). This hit in the HTS was further explored by using
the radioactive assay to screen the Enzo endocannabinoid library,
a collection of 60 compounds representing the combination of ten
acyl chains attached to six different amines (Table S1). These
compounds were tested at 1 and 10 mM for their ability to relievet 27, 2010 ª2010 Elsevier Ltd All rights reserved 897
Table 3. Bioactive PanK3 Activators with an EC50 < 10 mM
Activator EC50 (mM), HTS
a EC50 (mM), RA
b % Activation RA Annotated Activity
1,4-naphtoquinone 0.5 Inactive 0 Coal tar product
Phenylmercuric acidc 1.0 Inactive 0 Antifungal
Tamoxifen 3.4 4.0 140 Estrogen antagonist
Oleoylethanolamide 7.9 0.5 120 PPARa agonist
Palmitoyl-carnitine NDd 1.6 120 Metabolic intermediate
Oleoyl-carnitine ND 0.6 140 Metabolic intermediate
A bioactive compound library of 3200 unique compounds was initially screened at 12 mM to identify modulators of PanK3 activity (HTS). The activators
were then individually rescreened using a ten-point concentration series in triplicate. EC50 values calculated based on fitting the 30 data points to
a single site binding model, and the EC50 values were rounded to the nearest 0.1 mM (see Figure S1). The EC50 values and the percentage of maximal
activation of PanK3 with respect to the DMSO control were also determined using the PanK3 radioactive assay (RA). See Table S1 for the results from
the endocannabinoid library screen.
a High-throughput screening PanK3 assay.
b Radiochemical PanK3 assay.
c Phenylmercuric acid is an inhibitor of the luciferase reaction accounting for it appearing as a false activator in the HTS.
dND, not determined.
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endocannabinoid library screenwas performed in the presence of
acetyl-CoA because palmitoyl-carnitine activates PanK2 by
competing with the allosteric inhibitor, acetyl-CoA (Leonardi
et al., 2007a), and we were interested in evaluating the effective-
ness of potential activators to reverse acetyl-CoA inhibition.Within
the sameclass of compounds, an 18:1 acyl chain activated PanK3
morepotently than16:0 (Table S1), reflecting the higher potency of
oleoyl-carnitine compared with palmitoyl-carnitine as a PanK3
activator (Table 3). The screen revealed that acyl-glycines and
acyl-GABAs were more potent than the acyl-amides, -ethanola-
mides, -alanines, and -dopamines, but oleoyl-glycine and
oleoyl-GABAwerenotmorepotent activators thanoleoyl-carnitine
(Table 3; Table S1). We previously reported that PanK2 activation
by palmitoyl-carnitine was competitive with respect to acetyl-
CoA, and this regulatory event functions to increase theCoA levels
to support b-oxidation (Leonardi et al., 2007a). Competition
between acetyl-CoA and oleoyl-carnitine was also observed with
PanK3 (data not shown) and illustrates that PanK2 and PanK3
are regulated in a similar manner by acyl-carnitines. However,
these lipophilic activators are not suitable chemical scaffolds for
developing small molecule activators due to their hydrophobicity
andmetabolic instability.Tamoxifen isanestrogen receptorantag-
onist and was the second confirmed activator of PanK3 with an
EC50of 4mM(Table 3). Like the acyl-carnitines, tamoxifen reversed
the inhibition of PanK3 by acetyl-CoA (not shown) indicating that it
activates PanK3 by inhibiting the binding of acetyl-CoA. Thus,
tamoxifen activates PanK3 in a similar fashion to the activation of
Plasmodium falciparum PanK by furosemide (Lehane et al.,
2007), a drug that was present in two instances in our bioactive
library that did not make the cutoff for an activator of PanK3.
Modulation of CoA Biosynthesis in HepG2/C3A Cells
WeusedHepG2/C3A cells to test the effect of inhibitors and acti-
vators on CoA biosynthesis in a human liver cell line. RT-PCR
quantification of the PanK transcripts revealed that PanK3 was
the most abundant isoform (Figure 4A), thus making C3A cells
a good model system to test the ability of representatives from
each chemical class identified in the screen to modulate CoA
biosynthesis in intact cells. The thiazolidinediones, MCC-555898 Chemistry & Biology 17, 892–902, August 27, 2010 ª2010 Elseviand rosiglitazone, inhibited pantothenate incorporation into
CoA in C3A cells (Figure 4B). MCC-555 was a more potent
CoA biosynthesis inhibitor than rosiglitazone in this assay, corre-
lating with the biochemical assay (Figure 3A). Glyburide also
inhibited cellular CoA biosynthesis to a lesser extent than
MCC-555 (Figure 4B). Oleoyl-carnitine and oleoyl-ethanolamide
were activators of CoA biosynthesis in C3A cells (Figure 4B) but
were less potent in cells than in vitro, likely due to themetabolism
of the intermediates by the cells. Tamoxifen was the most potent
activator of CoA biosynthesis in cells (Figure 4B), reflecting the
in vitro activity of the compound (Table 3). These data showed
that PanK3 modulators identified in the screen modulated CoA
biosynthesis in intact cells. Although the PanK modulators
altered CoA synthesis in cell models, none of the compounds
identified in the bioactive screen are suitable experimental tools
to investigate PanK function due to their documented, higher
affinitiy effects on other protein targets.
Isoform Selectivity
PanK1b and PanK2 were purified and their responses to MCC-
555, glyburide, and tamoxifen were compared with their effect
on PanK3 (Figure S3). MCC-555 inhibited all three isoforms
with a rank order of PanK3 > PanK2 > PanK1b. PanK2 was
less sensitive to glyburide than PanK3, but PanK1b was acti-
vated rather than inhibited by this compound. In the case of
tamoxifen, PanK2 was not affected by this drug and PanK1b
was inhibited. A comparison of the CoA binding pockets of
PanK3 and PanK1b (Hong et al., 2007) reveals that Trp2660 is
replaced by Ser2660 and Tyr340 is replaced by Phe340, respec-
tively. It is tempting to suggest that these differences account
for the differential effect on the highly related PanK isoforms,
but this interpretation is likely too simplistic. The loop that forms
the lid of the tunnel is very flexible and may assume different
conformations depending on the structure of the bound ligand
that is sandwiched between the loop and the platform formed
by strands b10-b11. These data indicate that PanK1b inhibitors
can be obtained from an HTS screen using PanK3, and
that there are sufficient differences between the structures of
the PanKs that isoform-selective compounds can also be
identified.er Ltd All rights reserved
Figure 4. The Thiazolidinediones Inhibit CoA Biosynthesis in Cell
Culture
(A) Total RNA was extracted from HepG2/C3A cells and real-time PCR was
used to determine the relative abundance of the PanK isoform mRNA present
normalized to GAPDH as the calibrator.
(B) HepG2/C3A cells were labeled with [3H]pantothenate and the amount of
label incorporated into CoA was determined as described in Experimental
Procedures. The amount of incorporation in the control experiment in the pres-
ence of DMSOwas set at 100%, and the incorporation rates in the presence of
the test compounds was expressed as a percent of this value. Hopantenate
(Hopan), a known inhibitor of CoA biosynthesis (Zhang et al., 2007) was
used as a positive control, MCC-555, rosiglitazone (Rosiglit.), glyburide,
oleoyl-carnitine, oleoyl-ethanolaminde, and tamoxifen were tested at the
indicated concentrations. The data were duplicate measurements with the
standard error indicated by the bars.
Figure 5. Model of the PanK3 ‘‘Closed’’ Active Site
The model is based on the known structure of the homologous SaPanK closed
active site. Pantothenate (Pan) carbons are green, protein residues are yellow,
Mg2+ is a dark gray ball, and ATP carbons are gray. Predicted hydrogen bonds
are shown as dashed black lines. The protein backbone is transparent gray,
and the P loop is rendered as transparent magenta. Note that Glu138 is well
positioned to act as a general base, unlike the position shown in Figure 1D.
Also, the phosphate groups of ATP engage the P loop and the adenine ring
occupies a pocket that is distinct from that which binds the adenine ring of
acetyl-CoA (Figure 1D).
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An important advance in the understanding of the PanK catalysis
and regulation is the concept that the pantothenate substrate
binding site overlaps with the docking site for the allosteric
regulator, acetyl-CoA. A comparison between the PanK3,ace-
tyl-CoA and SaPanK,ATP,Mg2+ structures reveals that the
former is locked in an ‘‘open’’ conformation by acetyl-CoA.
This comparison allowed a model of the PanK3,pantothenate,
ATP,Mg2+ ‘‘closed’’ ternary complex to be generated from
the SaPanK structure (Figure 5). This model illustrates that
pantothenate binding at the same location as the pantothenate
portion of acetyl-CoA is consistent with the positioning of the
catalytic base, Glu138, and the g-phosphate of ATP in a complexChemistry & Biology 17, 89poised for phosphoryl transfer (Figure 5). The pantothenate
binding site is formed by strands b10 and b11 on the monomer
binding ATP,Mg2+ and the flexible a70-b130 loop from the oppo-
site monomer. The analogous region in the SaPanK,AMP-
PNP,Mg2+ binary complex is disordered in the structure (Hong
et al., 2006), which suggests that the a70-b130 substrate binding
loop is disordered in the absence of either acetyl-CoA or panto-
thenate. Indeed, the pantothenate portion of acetyl-CoA cannot
insert into the tight tunnel adjacent to the active site unless the
a70-b130 ‘lid’ moves away from the b10-b11 strands that form
the ‘‘floor’’ of the tunnel (Figures 1D). The structural alignment
between the two proteins shows that the Ser102/Arg113 pair
of SaPanK is analogous to Ser195/Arg207 of PanK3 consistent
with these residues playing a role in binding and orienting the
pantothenate substrate at the active site.
The comparison between SaPanK and PanK3 structures
indicates that the substrate and regulator binding domain
formed by the interaction between the monomers is not a static2–902, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 899
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Arg207 docking site on the rigid b10-b11 ‘‘floor’’ on the subunit
containing bound ATP,Mg2+, followed by the flexible a70-b130
loop on the opposite monomer closing over the substrate to
form a pantothenate-binding tunnel adjacent to the active site
that aligns the 40-hydroxyl for attack on the g-phosphate of
ATP catalyzed by the general base, Glu138. Direct evidence
for this binding mode for pantothenate comes from the analysis
of the PanK3(S195V) mutant, which is refractory to acetyl-CoA
inhibition and has a lower affinity for pantothenate and pante-
theine substrates. PanK3 also uses pantothenamides with alkyl
chains up to 7 carbons in length as substrates (Virga et al.,
2006), consistent with the substrate binding pocket in mamma-
lian PanKs being able to accommodate extended pantothenate
analogs. Finally, the PanK3(R207A), PanK3(A267F), and PanK3
(A269F) mutants bind ATP normally but are catalytically inactive,
supporting the conclusion that the tunnel architecture is impor-
tant not only for binding the allosteric inhibitor but also for
binding the pantothenate substrate. One caveat to this conclu-
sion is that pantothenate binds at a different location in the
PaPanK enzyme (Hong et al., 2006). Although PaPanK is struc-
turally related to PanK3 and SaPanK, the radically different
dimeric architecture ofPaPanK probably accounts for the unique
positioning of pantothenate in the PaPanK-pantothenate binary
complex (Hong et al., 2006). Unlike PanK3 and SaPanK, PaPanK
does not utilize the pantothenamide analogs as substrates
(Hong et al., 2006), illustrating that the substrate binding pocket
of PaPanK is different from the other pantothenate kinases.
This study identified two chemical scaffolds in the bioactive
compound library that bind to the acetyl-CoA regulatory site on
PanK3 and inhibit the enzyme. Interestingly, both the thiazolidi-
nediones and sulfonylureas identified in the primary screen
(Table 2) are used in the treatment of type 2 diabetes (Gale,
2001; Lehmann et al., 1995; Mudaliar and Henry, 2001; Bell,
2004; Boyd et al., 1990). The affinity of rosiglitazone for PanK3
is comparable to the affinity of this thiazolidinedione for the
free fatty acid receptor (Smith et al., 2009), another of its identi-
fied cellular targets. The SAR analysis shows that the highest
activity PPARg ligands or insulin secretagogues are not recog-
nized by PanK3. At the other end of the spectrum, MCC-555
has a 50-fold lower affinity for PPARg compared with rosigliti-
zone (Reginato et al., 1998), and the comparable potency of
this compound toward PanK3 suggests that PanK3 should be
given consideration as an off-target site of action. This is partic-
ularly interesting in light of the importance of CoA in supporting
b-oxidation and gluconeogenesis. Hopantenate, a competitive
inhibitor of PanK, reduces hepatic CoA levels leading to the
accumulation of triglycerides and hypoglycemia, which is exac-
erbated by fasting (Zhang et al., 2007). Two phenotypes of the
Pank1 knockout mouse are lower serum triglycerides and
glucose (Leonardi et al., 2010), suggesting that the pharmaco-
logical manipulation of CoA levels by PanK inhibitors may be
potentially useful in the management of metabolic disorders.
Also the genome-wide association of polymorphisms in the
PANK1 gene with insulin levels (Sabatti et al., 2009) shows that
PanK activity is associated with glucose homeostasis. These
findings indicate that PanK regulation of CoA biosynthesis plays
a key role in glucose homeostasis and fatty acid metabolism in
liver. The robust PanK HTS is poised to be deployed to screen900 Chemistry & Biology 17, 892–902, August 27, 2010 ª2010 Elsevilarger compound libraries to identify novel small molecules that
are suitable for development as general and isoform-selective
PanK modulators to probe the role of PanK in cell physiology
and potentially to pharmacologically adjust imbalances in inter-
mediary metabolism.
SIGNIFICANCE
The pantothenate kinases are a conserved group of proteins
that regulate the synthesis of CoA, a key cellular cofactor in
intermediary metabolism. The primary mechanism for PanK
regulation is feedback inhibition by acetyl-CoA, and the
discovery that this allosteric regulator docks to the panto-
thenate substrate site to block ATP binding provides a
molecular explanation for the stringency of PanK regulation.
The acetyl-CoA/pantothenate binding site consists of an
extensive surface formed by a rigid platform on the mono-
mer which binds ATP that engages a flexible segment from
the opposite monomer to sandwich either the substrate or
the allosteric regulator between the two monomers. This
interaction surface provides a binding site for small mole-
cules. PanK inhibitors and activators would be useful tools
to establish the role of the PanKs inmetabolismand disease.
The importance of CoA levels in supporting gluconeogen-
esis and fatty acid oxidation is evident from the effects of
CoA depletion in mice using the competitive PanK inhibitor
hopantenate and the analysis of Pank1 knockout mice.
Because PanK inhibition alters glucose and lipid homeo-
stasis, the cross-reactivity of the thiazolidinedione and
sulfonylurea scaffolds with PanK3 suggests that PanK
activity should be tested for a potential off-target effect
when considering the specificity of newly developed com-
pounds. There are two established roles for PanK in human
disease. Mutations in the PANK2 gene give rise to the neuro-
degenerative disorder known as PKAN, and a genome-wide
association study linked polymorphisms in the PANK1 gene
to insulin levels. This study shows that small molecule PanK
modulators can be identified and used to determine the
importance of regulating the intracellular CoA levels in inter-
mediary metabolism and disease.
EXPERIMENTAL PROCEDURES
Materials
Oligonucleotides were from the Hartwell Center at the St. Jude Children’s
Research Hospital; D-[1-14C]pantothenate (specific activity, 55 mCi/mmol)
was from American Radiolabeled Chemicals; TNP-ATP was from Molecular
Probes, Invitrogen; Kinase Glo Plus luminescent kinase assay was from Prom-
ega; the endocannabinoid library was from Enzo Life Sciences; DMEMpowder
medium lacking glucose, sodium pyruvate, pantothenate and glutamine
was from GIBCO. Pantetheine was prepared by incubating pantethine
(1.4mmol) in 6ml of 50mMTris-HCl (pH 8.0), 1MDTT for 1 hr at 60C. All other
reagents were of analytical grade or better.
Purification, Assay, and Kinetics of PanK3
PanK3wasmutagenized using theQuickChange site-directedmutagenesis kit
(Stratagene), as per manufacturer’s instructions. Wild-type and mutant PanK3
proteins were purified by affinity chromatography and gel filtration to homoge-
neity as described (Hong et al., 2007) by the St. Jude Protein Production
Facility. Enzymatic activity was determined in mixtures containing 45 mM
D-[1-14C]pantothenate (specific activity 22.5 mCi/mmol), 250 mM ATP,er Ltd All rights reserved
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50 ng to 1.6 mg. The KM for pantothenate was determined in reaction mixtures
containing 2–180 mM of this substrate and 10 mM ATP. The KM for ATP was
determined in reaction mixtures containing 45 mM of pantothenate and
increasing ATP concentrations from 4 mM to 1 mM. The same experiments
were repeated in the presence of 0, 200, and 625 mM ADP to elucidate the
kinetic mechanism. The potency of activators and inhibitors was evaluated
in standard mixtures containing 250 mM ATP, increasing concentrations of
the compound, and either 200 ng of PanK3, 10 ng of SaPanK, or 800 ng of
PanK3(S195V). Compounds of the endocannabinoid library were tested in
reactions containing 1.2 mM acetyl-CoA and 1 or 10 mM of each test
compounds. All reactions were incubated at 37C for 10min and then stopped
by the addition of 4 ml of 10% acetic acid. A 40 ml aliquot was deposited onto
a Whatmann DE81 ion-exchange filter disk that was washed in three changes
of 1% acetic acid/95% ethanol. Radioactive 40-phosphopantothenate was
quantified by counting each dried disk in 3 ml of scintillation fluid.High-Throughput Screening
The PanK3 HTS was performed using the St. Jude Children’s Research
Hospital (Memphis, TN USA) bioactive compound library consisting of 5600
(3200 unique) bioactive molecules. The sources were 1280 compounds from
Sigma (Cat #LO1280), 3200 compounds from Microsource (Gaylordsville,
CT; the ‘‘Spectrum Collection,’’ the ‘‘US Drug Collection,’’ and the ‘‘Killer
plates’’), and 1120 compounds from Prestwick (Illkirch, France; the ‘‘Prestwick
Chemical Library’’). The HTS assay is detailed in Supplemental Experimental
Procedures.CoA Biosynthesis in HepG2/C3A Cells
HepG2/C3A cells were cultured in EMEM medium supplemented with 10%
fetal bovine serum and 2mMglutamine, 50 U/ml penicillin, and 50 mg/ml strep-
tomycin. Labeling medium was prepared from glucose-, pantothenate-, pyru-
vate-, and glutamine-free DMEM medium reconstituted with 1 g/l glucose,
1 mM pyruvate, 2 mM glutamine, 1 mCi/ml [2,3-3H]pantothenic acid (specific
activity 50 Ci/mmol), and containing 4 mM octanoate, 5% dialyzed FBS,
50 U/ml penicillin, and 50 mg/ml streptomycin. Cells were seeded at a density
of 2–3 3 106 in 60 mm dishes and allowed to adhere overnight. The labeling
was initiated by replacing the medium with 2 ml of labeling medium containing
DMSO (control) or the test compound. Cells were incubated for 24 hr, the
labeling medium was removed, and cells were washed with phosphate-
buffered saline and lysed by the addition of 200 ml of 25% formic acid contain-
ing 50mMDTT. The lysates (80 ml) were deposited onto aWhatman DE81 filter
disk that was washed with three changes of 1% acetic acid/95% ethanol. [3H]
Phosphorylated metabolites were quantified by counting the dried disks. The
assay measures all intermediates downstream of pantothenate; however,
>98% of all of the radiolabeled metabolites are CoA based on chromato-
graphic analysis (Zhang et al., 2007).ACCESSION NUMBERS
The coordinates for the PanK3,acetyl-CoA binary complex have been depos-
ited in the Protein Data Bank with the accession number of 3MK6.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
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